Adimmune to shift vaccine research to focus on new COVID-19 variants

Taiwan's Adimmune Corp., which has fallen behind two other domestic pharmaceutical firms in the race to roll out a COVID-19 vaccine, said Wednesday that it will shift its focus to developing vaccines targeting new variants of the virus.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)